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Rationale: Cigarette smoking is a risk factor for diffuse parenchymal
lung disease. Risk factors for subclinical parenchymal lung disease
have not been described.
Objectives: To determine if cigarette smoking is associated with
subclinical parenchymal lung disease, as measured by spirometric
restriction and regions of high attenuation on computed tomogra-
phy (CT) imaging.
Methods: We examined 2,563 adults without airflow obstruction or
clinical cardiovascular disease in the Multi-Ethnic Study of Athero-
sclerosis, a population-based cohort sampled from six communities
in the United States. Cumulative and current cigarette smoking were
assessed by pack-years and urine cotinine, respectively. Spirometric
restriction was defined as a forced vital capacity less than the lower
limit of normal. High attenuation areas on the lung fields of cardiac
CT scans were defined as regions having an attenuation between
2600 and 2250 Hounsfield units, reflecting ground-glass and re-
ticular abnormalities. Generalized additive models were used to
adjust for age, gender, race/ethnicity, smoking status, anthropo-
metrics, center, and CT scan parameters.
Measurements and Main Results: The prevalence of spirometric re-
striction was 10.0% (95% confidence interval [CI], 8.9–11.2%) and
increased relatively by 8% (95% CI, 3–12%) for each 10 cigarette
pack-years in multivariate analysis. The median volume of high
attenuation areas was 119 cm3 (interquartile range, 100–143 cm3).
The volume of high attenuation areas increased by 1.6 cm3 (95% CI,
0.9–2.4 cm3) for each 10 cigarettepack-years in multivariate analysis.
Conclusions: Smoking may cause subclinical parenchymal lung dis-
ease detectable by spirometry and CT imaging, even among a gen-
erally healthy cohort.
Keywords: cigarette smoking; computed tomography; interstitial lung
disease; restrictive lung disease; spirometry
The diffuse parenchymal lung diseases (DPLDs) are characterized
by fibrosis and inflammation of the lung parenchyma, areas of high
attenuation on computed tomography (CT) scan, and reduced
FVC (1). Although some DPLDs are treatable, the most common
idiopathic form of DPLD, idiopathic pulmonary fibrosis (IPF), has
no proven therapies and carries a uniformly high mortality rate (2,
3). Identification of risk factors for IPF and other DPLDs might
allow for the development of preventative strategies.
Cigarette smoking is a putative risk factor for some of the
idiopathic interstitial pneumonias. For example, case series and
clinical experience suggest that desquamative interstitial pneumo-
nia and respiratory bronchiolitis-associated interstitial lung disease
are strongly linked to cigarette smoking (4, 5). Cigarette smoking
has also been associated with a greater risk for IPF in some (6–10)
but not all studies (11, 12). Each of these studies is limited by case-
control design and largely unadjusted analyses.Most also preceded
the modern understanding of this disease (2, 6–8, 11, 12).
Asymptomatic, early parenchymal lung disease has been
increasingly recognized and reported in family members of
affected individuals (10, 13–16). To date, however, only one
population-based study has examined risk factors for subclinical
parenchymal lung disease. In the U.S. National Health and
Nutrition Examination Survey (NHANES) I, current smokers
had an increased risk for spirometric restriction (reduced FVC
in the absence of airflow obstruction) compared with never
smokers, but former smokers had no increased risk; associations
with cumulative smoking (pack-years) were not reported (17).
Although suggestive, spirometric restriction has many possible
causes, only one of which is parenchymal lung disease.
In recent years, CT imaging has become the gold standard
noninvasive test to diagnose DPLD (1). Unlike spirometry,
CT imaging of the lungs has not generally been available in
population-based cohorts, despite the development of powerful
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Cigarette smoking is a risk factor for some idiopathic
interstitial pneumonias, and current smokers have a higher
prevalence of spirometric restriction. There are no pop-
ulation-based cohort studies examining the association
between cigarette smoking and increased lung density on
computed tomography (CT).
What This Study Adds to the Field
Smoking may cause subclinical parenchymal lung disease
detectable by spirometry and CT imaging.
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tools for quantitating parenchymal lung disease noninvasively
with CT (18). The Multi-Ethnic Study of Atherosclerosis
(MESA) is a population-based prospective cohort study that
enrolled older adults without clinical cardiovascular disease.
MESA participants underwent cardiac CT scanning that imaged
most of the lung parenchyma, offering the opportunity to
identify risk factors for subclinical parenchymal lung disease.
Therefore, we examined the relationships between cigarette
smoking, spirometric restriction, and increased lung attenuation
by CT imaging in MESA. We hypothesized that a greater
number of pack-years of cigarette smoking would be associated
with a higher prevalence of spirometric restriction and a greater
volume of high CT attenuation in the lung parenchyma in-
dependent of obesity and other potential confounding factors in
participants without evidence of airflow obstruction. Some of
the results of this study have been previously reported in the
form of an abstract (19).
METHODS
MESA
MESA is a multicenter prospective cohort study to investigate the
prevalence, correlates, and progression of subclinical cardiovascular
disease in individuals without clinical cardiovascular disease (http://
www.mesa-nhlbi.org) (20). In 2000 to 2002, MESA recruited 6,814 men
and women aged 45 to 84 years old from six United States communi-
ties: Forsyth County, NC; northern New York County and Bronx County,
NY; Baltimore City and Baltimore County, MD; St. Paul, MN; Chicago,
IL; and Los Angeles, CA. MESA participants are white, African
American, Hispanic, or Asian (mostly of Chinese origin). Exclusion cri-
teria included clinical cardiovascular disease, weight greater than 136 kg,
any impediment to long-term participation, and chest CT within the past
year. The protocols of MESA and all studies described herein were
approved by the Institutional Review Boards of all collaborating
institutions and the National Heart, Lung, and Blood Institute.
The MESA-Lung Study
The MESA-Lung Study enrolled 3,965 of 4,484 eligible MESA
participants who had consented to genetic analyses, undergone base-
line measures of endothelial function, and attended an examination
during the MESA-Lung recruitment period in 2004 to 2006 (Figure 1).
Chinese Americans were over-sampled to improve the precision of
estimates for this group.
In the current study, we excluded 72 participants who did not
complete spirometry, 180 with less than two acceptable spirometry
maneuvers, 231 who did not reach a volume-time plateau, 756 with
airflow obstruction (an FEV1/FVC ratio less than 0.70), and 163 with
incomplete data for pack-years or cotinine.
Spirometry
Spirometry was performed according to American Thoracic Society/
European Respiratory Society guidelines (see online supplement) (21).
We defined spirometric restriction as an FVC less than the lower limit
of normal according to NHANES III race-specific reference equations
(22). Because references equations for Asian Americans were not
available from the NHANES III study, we used a 0.88 correction factor
for the predicted FVC for Chinese Americans (23).
Lung Attenuation on CT Scan
Quantitative measures of lung attenuation were performed on the lung
fields of MESA cardiac CT scans, which image approximately 70% of
the lung volume from the carina to lung bases (24). CT scans were
performed during the years 2000 to 2002 on multidetector CT scanners
(three sites) and electron beam tomography scanners (three sites) using
a standardized protocol (25). Two sequential scans on separate breath-
holds were performed in succession at full inspiration on each par-
ticipant. The scan with higher air volume was used for analyses, except
in cases of discordant scan quality control score, in which case the
higher-quality scan was used (24). Image attenuation was assessed
using a modified version of the Pulmonary Analysis Software Suite
(26–29) at a single reading center by trained readers without knowl-
edge of smoking history. Scanner calibration methods in MESA for
coronary calcium have been previously published (25) and are de-
scribed in the online supplement. To account for variation in scanner
calibration at 21,000 Hounsfield units (HU), attenuation of air outside
the body was measured for each scan and the attenuation of each pixel
was corrected to have the value: (21,000 3 measured pixel attenua-
tion)/mean air attenuation.
CT Definition of Subclinical Parenchymal Lung Disease
We are not aware of an established definition of either DLPD or
subclinical parenchymal lung disease using quantitative CT measures.
Therefore, we defined subclinical parenchymal lung disease as high
attenuation areas (HAAs) within the lung fields having a CT attenu-
ation value between 2600 and 2250 HU (Figure 2). This range of CT
lung attenuation includes ground-glass and reticular abnormalities and
is low enough to clearly exclude more dense areas, such as complete
atelectasis, medium and large blood vessels, and pulmonary nodules,
which are all more dense than water (HU of 0) (30, 31). The intraclass
correlation coefficient of HAA among the 100% replicate CT scans
was 0.93 (n 5 2,653).
We validated HAA expressed as a percentage of the total lung
volume imaged on cardiac CT scans against full-lung CT scans in 42
MESA participants. The Spearman correlation coefficient of HAA
between cardiac and full-lung scans was 0.87 and the mean difference
was 0.2% (95% limits of agreement 22.5 to 13.0%).
A board-certified thoracic radiologist and a board-certified pulmo-
nologist independently reviewed the lung fields of 101 CT scans
sampled randomly among participants with greater than 10% HAA
by volume (95th percentile of HAA) and less than 10% HAA.
Reviewers were blinded to the HAA values of the scans and were
not permitted to quantify voxel attenuation using imaging software.
Statistical Analysis
For descriptive purposes, the cohort was stratified by pack-years of
cigarette smoking. We estimated prevalence ratios using Poisson
regression with robust standard errors in generalized linear models
(32). All continuous variables had linear relationships with the natural
log prevalence of spirometric restriction. For the lung attenuation
analysis, generalized additive models with loess smoothing functions
for continuous variables were used to allow for the flexible specification
of relationships and to minimize misspecification of potential con-
founding variables. The volume of HAAs was regressed on pack-years
controlling for the total volume of imaged lung and other covariates.
We chose this approach instead of expressing HAA as a percentage of
the imaged lung volume because the latter approach specifies the
dependent variable as a ratio, which may induce spurious correlations
(33). Statistical significance was defined as two-tailed P values less than
0.05. Analyses were performed using SAS 9.1 (SAS Institute, Cary,
NC) and the gam function in R 2.6 (R Foundation, Vienna, Austria).
RESULTS
The mean age of the 2,563 participants was 64 6 9 years, and
44% were men. Thirty-three percent were white, 24% were
African American, 25% were Hispanic, and 18% were Chinese
American. Eight percent were current and 37% were former
smokers, with a median number of cigarette pack-years of
15 (interquartile range 5–31). Participants with heavier smok-
ing histories were more likely to be white, male, and obese
(Table 1).
Spirometric Restriction
The prevalence of spirometric restriction was 10.0% (95%
confidence interval [CI], 8.9–11.2%) overall and was highest
among the heaviest smokers (Table 2). After adjustment for
demographics, the prevalence of spirometric restriction in-
creased by 10% for every 10 cigarette pack-years smoked
(95% CI, 7–14%). Additional adjustment for smoking status,
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urine cotinine level, and anthropometrics did not meaningfully
change this association. The nonlinear model (Figure 3A) did
not fit the data better than the linear model, suggesting that the
relationship between pack-years and spirometric restriction was
linear.
Similarly, a higher urine cotinine concentration was associ-
ated with a greater prevalence of spirometric restriction even
after adjusting for demographics, cigarette pack-years, and
anthropometrics (5% increase in the prevalence of spirometric
restriction per 1 mg/ml increase in urine cotinine; 95% CI, 1–9%;
Table 3).
HAAs
HAA greater than 10% was sensitive and specific for areas of
high attenuation suggestive of clinically relevant abnormalities
identified by visual readings. Sensitivity of HAA greater than
10% was 81 and 78% compared with qualitative readings by
a board-certified thoracic radiologist and board-certified pul-
monologist, respectively. Specificity of HAA greater than 10%
was 64 and 91%, respectively. Interobserver agreement was
71% and interobserver k was 0.45. After excluding scans with
breath artifacts, k was 0.60. Among the 56 scans with greater
than 10% HAA, the most common abnormalities detected were
ground-glass opacities or atelectasis (radiologist: 34, pulmonol-
ogist: 52), reticular abnormalities (radiologist: 2, pulmonologist:
5), possible or probable usual interstitial pneumonia pattern
(radiologist: 6, pulmonologist: 1), definite usual interstitial pneu-
monia (UIP) pattern (radiologist: 1, pulmonologist: 0), and focal
scar (radiologist: 5, pulmonologist: 3).
Figure 2 shows histograms of CT lung attenuation and
representative CT images of the lungs from three study subjects
at the median (119 cm3), 75th percentile (143 cm3), and 95th
percentile (202 cm3) of HAA. HAA was greater among those
with spirometric restriction compared with those with normal
spirometry (age-, sex-, and race-adjusted mean difference of
5.0 cm3, 95% CI 0.1 to 9.9 cm3; P 5 0.04).
HAA increased across categories of pack-years (Table 2).
After adjusting for demographics, HAA increased by 2.5 cm3
(95% CI, 1.8–3.3 cm3) for each 10 cigarette pack-years. Addi-
tional adjustment for smoking status, urine cotinine, and
anthropometrics attenuated this association, but it remained
significant in the fully adjusted model. The nonlinear model
(Figure 3B) did not fit the data better than the linear model,
suggesting that the relationship between pack-years and HAA
was linear. A fully adjusted model limited to former and never
smokers showed similar findings (mean increase of 1.8 cm3 of
Figure 1. Participants in the Multi-Ethnic Study of
Atherosclerosis–Lung study included in the present
analysis.
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HAAs per 10 cigarette pack-years; 95% CI, 1.0–2.7; n 5 2,253).
Limiting the fully adjusted model to the subgroup with normal
body mass index (20–25 kg/m2) showed similar results (mean
increase of 2.8 cm3 of HAAs per 10 cigarette pack-years; 95%
CI, 1.5–4.2 cm3; n 5 654).
A higher urine cotinine level was also associated with a
greater volume of high lung attenuation even after adjusting
for demographics, cigarette pack-years, and anthropometrics
(mean increase of 2.0 cm3 of HAAs per 1 mg/ml increase in
urine cotinine; 95% CI, 1.4–2.7 cm3; Table 3).
Additional Analyses
Additional analyses are presented in Table E2 in the online
data supplement. Decreased kurtosis and skewness of the lung
histogram are characteristically observed in patients with DPLD
and correlate with measures of disease severity (30). In our
study, greater cigarette pack-years were associated with de-
creased kurtosis and skewness (Table E2).
We also explored the effect of potential confounders on our
results (Table E2). Neither stratification by type of CT scanner
nor exclusion of scans of suboptimal quality affected our
findings. Exclusion of those with chest wall or pleural disease
alone (n 5 39) or those with any self-reported chest disease
(n 5 100) did not change our findings. Similarly, exclusion of
participants with reduced left ventricular function or wall mo-
tion abnormalities; occupational exposure to dusts, gases, or
fumes; tricyclic antidepressant use; coronary artery calcification;
or obesity led to similar results (Table E2).
Inclusion of 350 participants with an FEV1/FVC ratio less
than 0.70 but greater than the lower limit of normal gave similar
TABLE 1. CHARACTERISTICS OF 2,563 MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS PARTICIPANTS WITHOUT
AIRFLOW OBSTRUCTION
Cigarette Pack-Years
N 0 1–10 11–20 .20
No. of subjects 1,444 432 235 452
Demographics and anthropometrics 2,563
Age at spirometry, years 64 6 10 64 6 9 64 6 10 64 6 9
Men, % 35 52 54 60
Race/ethnicity
White, % 29 32 42 44
African American, % 22 28 29 28
Chinese American, % 25 9 8 9
Hispanic, % 25 31 23 19
Height, cm 163 6 10 167 6 10 167 6 9 168 6 10
Weight, kg 75 6 17 81 6 17 81 6 17 84 6 18
Body mass index, kg/m2 28 6 5 29 6 6 29 6 6 30 6 6
Body mass index category, kg/m2
,25 32 22 27 22
25–29.9 39 44 44 39
30–39.9 27 29 26 34
>40 2 5 4 5
Waist circumference, cm 96 6 14 100 6 15 98 6 14 100 6 14
Hip circumference, cm 104 6 11 107 6 12 106 6 12 107 6 12
Smoking 2,563
Never smoker, % 98 0 0 0
Former smoker, % 2 90 84 75
Current smoker, % 0 10 16 25
Cigarette pack-years (among ever-smokers) 4 (2–7) 15 (3–17) 36 (27–50)
Urine cotinine, mg/ml (among current smokers) 1.0 (0.1–3.1) 3.7 (1.5–5.8) 5.2 (2.3–9.0)
Spirometry 2,563
FEV1, L 2.4 6 0.7 2.6 6 0.7 2.6 6 0.7 2.6 6 0.7
FEV1, % predicted 98 6 15 98 6 16 98 6 17 94 6 16
FVC, L 3.0 6 0.9 3.4 6 1.0 3.4 6 0.9 3.3 6 1.0
FVC, % predicted 96 6 15 97 6 16 96 6 16 93 6 16
FEV1/FVC ratio 0.79 6 0.05 0.78 6 0.05 0.78 6 0.05 0.78 6 0.05
Forced expiratory time 100%, s 10 6 2 11 6 3 11 6 3 11 6 3
Computed tomography 2,563
Type of CT scanner
Multidetector CT 66 57 52 50
Electron beam tomography 34 43 48 50
Total imaged lung volume (gas 1 tissue), cm3 2,510 6 686 2,769 6 734 2,867 6 680 2,899 6 657
Pulmonary gas volume, cm3 2,096 6 633 2,325 6 676 2,410 6 630 2,417 6 605
Pulmonary tissue volume, cm3 413 6 83 443 6 88 457 6 82 482 6 90
Emphysema, %* 15 (8–24) 17 (10–26) 18 (9–28) 15 (8–25)
Respiratory diseases†
History of respiratory problems before age 16 yr, % 2,531 6 7 7 7
Self-reported asthma before the age of 45, % 2,563 7 7 6 5
Self-reported pulmonary fibrosis, % 2,540 0.1 0 0.4 0.2
Self-reported emphysema, % 2,563 0.1 0.2 0 1.8
Self-reported history of tuberculosis, % 2,563 0.01 0.01 0.01 0.02
Data are mean 6 SD, median (interquartile range), and percentage.
* Percent emphysema is the percentage of the total voxels in the whole lung that fell below 2910 Hounsfield units.
† Additional self-reported chest diseases are reported in Table E1 in the online data supplement.
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results (22). Inclusion of 715 participants with airflow obstruc-
tion did not alter our findings.
In a post hoc analysis, the association between pack-years
and CT lung attenuation was different for men compared with
women. The mean increase in HAA per 10 pack-years was
2.3 cm3 (95% CI, 1.4–3.3 cm3) for men compared with 0.6 cm3
(95% CI, 20.6 to 1.9 cm3) for women (P for interaction 5
0.005) in fully adjusted models. We did not detect a similar
gender difference for the association of pack-years with spiro-
metric restriction.
DISCUSSION
This is the first study to examine the association between
cumulative cigarette smoking and areas of increased lung atten-
uation on CT in a large population-based cohort. To do so, we
defined a novel measure of increased CT lung attenuation,
HAA, that accurately predicts the presence of parenchymal
lung abnormalities. Higher HAA and spirometric restriction
were both associated with a greater number of pack-years of
cigarettes smoked independent of body size, current smoking
status, and other potential confounders. Our findings support
the hypothesis that cigarette smoking is a risk factor for pa-
renchymal lung abnormalities other than emphysema.
Mannino and coworkers previously identified current smok-
ing status as an independent risk factor for spirometric re-
TABLE 2. ASSOCIATIONS BETWEEN CIGARETTE PACK-YEARS, SPIROMETRIC RESTRICTION, AND AREAS OF HIGH ATTENUATION ON
LUNG COMPUTED TOMOGRAPHY
Cigarette Pack-Years
P for
Trend
Effect Estimate
per 10 Pack-Years
(95% CI) P Value0 1–10 11–20 .20
No. of subjects 1,444 432 235 452 2,563
Prevalence of spirometric restriction 9% 8% 9% 16% ,0.001
Prevalence ratios for spirometric restriction
Age, sex, and race/ethnicity-adjusted 1 (Ref) 0.8 0.9 1.6 0.003 1.10 (1.07–1.14) ,0.001
Age, sex, race/ethnicity, smoking status, and urine cotinine-adjusted 1 (Ref) 0.8 0.9 1.5 0.02 1.09 (1.05–1.14) ,0.001
Full multivariate model 1 (Ref) 0.8 0.8 1.4 0.08 1.08 (1.03–1.12) ,0.001
HAA volume, cm3* 122 130 131 140 ,0.001
Mean increase in HAA volume, cm3*
Age, sex, and race/ethnicity-adjusted 0 (Ref) 2.4 5.0 14.0 ,0.001 2.5 (1.8–3.3) ,0.001
Age, sex, race/ethnicity, smoking status, and urine cotinine-adjusted 0 (Ref) 2.1 3.7 10.9 ,0.001 2.0 (1.2–2.8) ,0.001
Full multivariate model 0 (Ref) 1.0 3.3 9.2 ,0.001 1.6 (0.9–2.4) ,0.001
Definition of abbreviations: CI 5 confidence interval; HAA 5 high attenuation area.
Prevalence ratios are from generalized linear models. Mean increases are from generalized additive models with loess smoothers for continuous covariates. Linear
estimates are presented. The full multivariate model includes age, sex, race/ethnicity, smoking status, urine cotinine, height, body mass index, hip circumference, and
waist circumference. All HAA models are further adjusted for study site, total volume of imaged lung, and milliampere dose.
* High attenuation areas (HAAs) are regions of lung with an attenuation between 2600 and 2250 Hounsfield units.
Figure 2. (A) Histograms of lung attenuation and (B–D) representative
computed tomography images of three study participants at the (B)
50th, (C ) 75th, and (D) 95th percentiles of high attenuation area (119,
143, and 202 cm3 of HAAs, respectively). The differences in the number
of HAAs (2600 to 2250 Hounsfield units) appear small on visual
inspection of the histograms in A. However, there are notable differ-
ences in the peakedness (kurtosis) and skewness of the three histo-
grams, with lower kurtosis and skewness as the number of HAAs
increases. Areas of increased attenuation appear gray and white on
the lung windows shown in C and D.
TABLE 3. ASSOCIATIONS BETWEEN URINE COTININE,
SPIROMETRIC RESTRICTION, AND AREAS OF HIGH
ATTENUATION ON LUNG COMPUTED TOMOGRAPHY
Effect Estimate
(95% CI) per
1 mg/ml Increase
in Urine Cotinine P Value
No. of subjects 2,563
Prevalence ratios for spirometric restriction
Age, sex, and race/ethnicity-adjusted 1.07 (1.03–1.11) ,0.001
Age, sex, race/ethnicity, pack-years–adjusted 1.04 (1.01–1.08) 0.03
Full multivariate model 1.05 (1.01–1.09) 0.02
Mean increase in HAA volume, cm3*
Age, sex, and race/ethnicity-adjusted 2.4 (1.7–3.1) ,0.001
Age, sex, race/ethnicity, pack-years–adjusted 1.8 (1.1–2.5) ,0.001
Full multivariate model 2.0 (1.4–2.7) ,0.001
Definition of abbreviations: CI 5 confidence interval; HAA 5 high attenuation
area.
Prevalence ratios are from generalized linear models. Mean increases are from
generalized additive models with loess smoothers for continuous covariates.
Linear estimates are presented. The full multivariate model includes age, sex,
race/ethnicity, cigarette pack-years, height, body mass index, hip circumference,
and waist circumference. All HAA models are further adjusted for study site, total
volume of imaged lung, and milliampere dose.
* HAAs are regions of lung with an attenuation between 2600 and 2250
Hounsfield units.
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striction in 4,320 participants in the NHANES I study (17),
a finding we confirmed using urine cotinine, a biological marker
of current smoking. In the NHANES study, current smoking
was associated with a 40% increased odds of spirometric
restriction after adjusting for potential confounders, an effect
estimate similar in magnitude to the 40% increase in the prev-
alence of spirometric restriction we detected in heavy smokers
(.20 pack-years) compared with never smokers. Our study
builds on this important previous work by showing that
cumulative cigarette smoke exposure is associated with spiro-
metric restriction and areas of increased lung attenuation on CT
independent of current smoking status, providing the first
evidence that cigarette smoking might lead directly to increases
in lung density even without a formal diagnosis of DPLD.
The increased HAA we observed in heavy smokers might
represent pathological changes in the lung, such as interstitial
inflammation or fibrosis. Despite a number of case-control
studies linking cigarette smoking to IPF (6–9), the mechanisms
underlying this association are not well established. Cigarette
smoke can injure endothelial and alveolar epithelial cells by
increasing oxidative stress (34–36) and enhancing virus-induced
parenchymal inflammation (37). Such injury could lead to
abnormal wound healing and parenchymal fibrosis in suscepti-
ble individuals. In an animal model, cigarette smoke also in-
creases the number of pulmonary myofibroblasts and enhances
the fibrotic response to bleomycin, possibly by increasing matrix
metalloproteinase-9 levels (38), and may further promote fi-
brosis by stimulating release of transforming growth factor-b1
from fibroblasts (39). Our findings should direct additional
effort toward understanding the role of cigarette smoking in
the development of pulmonary parenchymal fibrosis and in-
flammation.
Cigarette smoke is also a well-known cause of airway
changes, such as mucous hypersecretion, airway inflammation,
and increases in airway wall thickness. The airways of cigarette
smokers are characterized by increases in inflammatory cells,
which can persist after smoking cessation (40). We excluded
large airways from our quantitative assessment of CT lung
density, minimizing the impact of airway inflammation on our
findings. Small-airway inflammation and bronchiolocentric fi-
brosis, however, may have contributed to our results. Neverthe-
less, because our findings were unchanged by the exclusion of
current smokers, it is unlikely that respiratory bronchiolitis or
alveolar macrophage accumulation completely accounts for our
findings.
Pulmonary edema also increases lung attenuation. Cigarette
smoking could increase lung water by affecting left ventricular
function. However, clinical cardiovascular disease, including
heart failure, was an exclusion criterion, and our results re-
mained unchanged after excluding those with decreased left
ventricular function or wall motion abnormalities, minimizing
the likelihood that our findings represent increases in pulmo-
nary edema.
Our study had several limitations. First, we retrospectively
ascertained cigarette pack-years and smoking status, introduc-
ing the potential for information bias. To minimize misclassifi-
cation of these key exposures, we ascertained the number of
cigarette pack-years using standardized and supplemental meth-
ods and measured urine cotinine, an established indicator of
recent tobacco smoke exposure (41).
Second, although smoking is an established risk factor for
chronic obstructive pulmonary disease its association with
DPLD is less certain; unmeasured confounders could be re-
sponsible for some or all of the associations we observed. For
example, obesity is a frequent cause of reductions in lung
volume due to changes in chest wall compliance and diaphrag-
matic efficiency (42–45), and abdominal obesity has recently
been shown to be a critical factor contributing to spirometric
restriction (46). In our study, obesity was associated with
cigarette smoking. To avoid confounding by body size, we used
flexible modeling of precisely measured anthropometric factors,
such as body mass index, height, and hip and waist circum-
ferences, and we found consistent results among participants
with a normal body mass index. Nonetheless, residual con-
founding by body size cannot be entirely excluded. The lack of
putative risk factors for IPF and other idiopathic interstitial
pneumonias limits our ability to examine additional confound-
ing factors.
Third, static lung volumes were not measured in MESA. A
restrictive ventilatory defect is defined as ‘‘a reduction in total
lung capacity below the 5th percentile of the predicted value,
and a normal FEV1/vital capacity’’ and therefore requires
measurement of lung volumes by plethysmography, gas di-
lution, or gas washout techniques (47). Among patients referred
to a pulmonary function laboratory, spirometric restriction is
associated with a low total lung capacity only about half of the
Figure 3. Continuous relationships
of cigarette pack-years to (A) spiro-
metric restriction and (B) the vol-
ume of high lung attenuation. Thick
dotted lines: smoothed regression
lines adjusted for age, gender,
race/ethnicity, current smoking sta-
tus, urine cotinine, height, body
mass index, and waist and hip cir-
cumferences. B is further adjusted
for study site, total volume of im-
aged lung, and milliampere dose.
Thin solid lines: 95% confidence
intervals. Neither smoothed curve
differed significantly from a straight
line (A: P 5 0.65; B: P 5 0.16),
suggesting that the relationships
between cigarette pack-years and
both measures are linear. Multivar-
iate-adjusted (predicted) probabilities of spirometric restriction were estimated by combining the prevalence of spirometric restriction in the sample
with the predicted incremental probabilities of spirometric restriction using a generalized additive model. Multivariate-adjusted (predicted) values of
HAA were estimated by adding the sample mean to predicted mean differences using a generalized additive model.
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time (48, 49). On the other hand, CT measures are particularly
sensitive for changes in the pulmonary parenchyma, and our
findings were consistent across both measures of subclinical
parenchymal lung disease.
Fourth, we created a new measure, HAA, for epidemiologic
research, because there is no current standard. We chose
a reasonable range of lung density (2600 to 2250 HU) that
represents typical ground-glass opacities and interstitial thick-
ening, while clearly excluding areas devoid of air, such as com-
plete atelectasis and consolidation (31). While scanning during
diaphragmatic motion or incomplete inspiration can also lead to
areas of increased lung attenuation, our results remained un-
changed after excluding scans of suboptimal quality. Our
measure was highly reproducible between scans and showed
moderate agreement between expert reviewers. In addition,
findings for the alternative measures of kurtosis and skewness
showed consistency with our new measure and with previous
studies of interstitial disease (30).
Fifth, although we ascertained CT lung attenuation using
partial lung scans obtained to assess coronary calcium, most
idiopathic DPLDs preferentially involve the lower lobes, which
were virtually completely imaged. In addition, our new measure
correlated strongly with measures from full-lung CT scans.
Finally, the association between cigarette pack-years and
HAAs was relatively small: the increase in HAAs for each 10
cigarette pack-years was equal in magnitude to 4% of its
standard deviation. An association of this magnitude should
be expected in a healthy cohort, likely representing subclinical
parenchymal changes. Larger effect sizes might be expected
only in those with clinical DPLD.
In conclusion, we found that cumulative and current cigarette
smoking were both independently associated with spirometric
restriction and increased CT lung attenuation in a population-
based sample of older adults without airflow obstruction or
clinical cardiovascular disease. Our findings support the hypoth-
esis that smoking is a risk factor for subclinical parenchymal
inflammation and/or fibrosis.
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